Cambrex Corporation (CBM) reported quarterly earnings results on Friday, Apr-29-2016. The company said it had a profit of $0.50 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.16. Analysts had a consensus of $0.34. The company posted revenue of $94.74 million in the period, compared to analysts expectations of $82.87 million. The company’s revenue was up 22.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 EPS.
Many Wall Street Analysts have commented on Cambrex Corporation. Shares were Reiterated by Singular Research on Feb 11, 2016 to “Buy” and Lowered the Price Target to $ 60 from a previous price target of $63 .Cambrex Corporation was Initiated by Sidoti to “Buy” on Feb 1, 2016.
Cambrex Corporation closed down -0.28 points or -0.62% at $44.82 with 2,75,709 shares getting traded on Wednesday. Post opening the session at $44.91, the shares hit an intraday low of $44.08 and an intraday high of $45.12 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Mar 17, 2016, Steven M Klosk (President & CEO) sold 19,565 shares at $41.00 per share price. According to the SEC, on Mar 16, 2016, Louis J. Grabowsky (director) purchased 750 shares at $40.10 per share price. On Mar 11, 2016, Gregory Sargen (Executive Vice President & CFO) sold 26,697 shares at $41.37 per share price, according to the Form-4 filing with the securities and exchange commission.
Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company’s customers include generic drug companies and companies that discover and commercialize small molecule human therapeutics using organic chemistry. Its business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs) pharmaceutical intermediates and to a lesser extent other fine chemicals. Cambrex has three operating segments which are manufacturing facilities that have been aggregated as one reportable segment.